CoChat

Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial

Open access

The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.

Abstract

The US Food and Drug Association has approved interferon-α (IFN-α) and interleukin-2 (IL-2) as adjuvant therapy in malignant melanoma. The objective of the study was to compare efficacy and safety of subcutaneous interferon-α with continuous intravenous IL-2 in Chinese patients with malignant melanoma. A total of 250 patients with unresectable malignant melanoma were subjected to randomized in 1 : 1 ratio. Patients received subcutaneous 9×10 IU/m IFN-α (IFN-α group, n=125) or continuous intravenous 9×10 IU/m IL-2 (IL-2 group, n=125) at every 21 days for 4 months. The response, progression-free survival, overall survival, adverse effects, and cost were evaluated by experts in the field. IL-2 and IFN-α were effective in improvement of malignant melanoma after 4 months of intervention. IL-2 was effective in improving brain metastasis. Patients of the IL-2 group had a higher overall survival (P<0.0001) and a higher progression-free survival (P=0.002) than those of IFN-α group. The IL-2 group reported hypotension, kidney dysfunction, liver dysfunctions, flu-like symptoms, and capillary leak syndrome as adverse effects. IFN-α group reported thrombocytopenia and neutropenia as adverse effects. Healthcare management and expert charges lead to increase in the cost of treatment for IL-2 group patients than IFN-α group (P<0.0001). Continuous intravenous IL-2 should be recommended in relapse-free Chinese patients with malignant melanoma. Level of Evidence: I.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cad.0000000000000741

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CONSORT flow diagram of the study. Two-sided confidence intervals: 80%, outcome in both groups: 95%, the risk ratio detected: 1, and normal approximation: 9.917%. Intention-to-treat method of analysis was adopted.
Fig. 1 CONSORT flow diagram of the study. Two-sided confidence intervals: 80%, outcome in both groups: 95%, the risk ratio detected: 1, and normal approximation: 9.917%. Intention-to-treat method of analysis was adopted.CC BY-NC-ND · PubMed Central
Fig. 2 (a) Brain metastasis before treatment. MRI of the brain of a patient with cutaneous melanoma at the time of the enrollment. ECOG status: 2. Breslow thickness: 1.8 mm. Line indicates tumor. (b) The treatment response for interleukin-2. MRI of the brain of a patient with cutaneous melanoma after 4 months of interleukin-2 intervention. ECOG status after intervention: 1. Breslow thickness after intervention: 0.9 mm. Tumor was absent after intervention. Patient age 48 years. Sex: male. The site of melanoma: left lower extremity.
Fig. 2 (a) Brain metastasis before treatment. MRI of the brain of a patient with cutaneous melanoma at the time of the enrollment. ECOG status: 2. Breslow thickness: 1.8 mm. Line indicates tumor. (b) The treatment response for interleukin-2. MRI of the brain of a patient with cutaneous melanoma after 4 months of interleukin-2 intervention. ECOG status after intervention: 1. Breslow thickness after intervention: 0.9 mm. Tumor was absent after intervention. Patient age 48 years. Sex: male. The site of melanoma: left lower extremity.CC BY-NC-ND · PubMed Central
Fig. 3 (a) Patient with ulcerated cutaneous melanoma at the time of the enrollment. ECOG status: 2. Breslow thickness: 2.5 mm. (b) Patient with cutaneous melanoma after 4 months of interleukin-2 intervention. ECOG status after intervention: 2. Breslow thickness after intervention: 2.0 mm. Patient age 32 years. Sex: male. The site of melanoma: left lower extremity. The RECIST v1.1 guideline was used for evaluation of tumor response.
Fig. 3 (a) Patient with ulcerated cutaneous melanoma at the time of the enrollment. ECOG status: 2. Breslow thickness: 2.5 mm. (b) Patient with cutaneous melanoma after 4 months of interleukin-2 intervention. ECOG status after intervention: 2. Breslow thickness after intervention: 2.0 mm. Patient age 32 years. Sex: male. The site of melanoma: left lower extremity. The RECIST v1.1 guideline was used for evaluation of tumor response.CC BY-NC-ND · PubMed Central
Fig. 4 (a) Patient with cutaneous melanoma at the time of the enrollment. ECOG status: 1. Breslow thickness: 0.8 mm. (b) Patient with cutaneous melanoma after 4 months of Interferon-α intervention. ECOG status after intervention: 1. Breslow thickness after intervention: 0.6 mm. Patient age 55 years. Sex: female. The site of melanoma: Left lower extremity. The RECIST v1.1 guideline was used for evaluation of tumor response.
Fig. 4 (a) Patient with cutaneous melanoma at the time of the enrollment. ECOG status: 1. Breslow thickness: 0.8 mm. (b) Patient with cutaneous melanoma after 4 months of Interferon-α intervention. ECOG status after intervention: 1. Breslow thickness after intervention: 0.6 mm. Patient age 55 years. Sex: female. The site of melanoma: Left lower extremity. The RECIST v1.1 guideline was used for evaluation of tumor response.CC BY-NC-ND · PubMed Central
Fig. 5 Overall survival of the patients. Overall survival was considered from the time of detection of malignant melanoma to the death. 0: At the time of completion of the intervention. The χ2-independence test was used for statistical analysis. A P<0.05 was considered significant. The sample size: 125 for both groups. Data were represented as mean±SD of all.
Fig. 5 Overall survival of the patients. Overall survival was considered from the time of detection of malignant melanoma to the death. 0: At the time of completion of the intervention. The χ2-independence test was used for statistical analysis. A P<0.05 was considered significant. The sample size: 125 for both groups. Data were represented as mean±SD of all.CC BY-NC-ND · PubMed Central
Fig. 6 Progression-free survival of patients. Progression-free survival of patients was considered as time without any progression to new cutaneous/subcutaneous metastases (skin), lymph node metastases, or distant metastases (systemic). 0: At the time of completion of the intervention. The χ2-independence test was used for statistical analysis. A P<0.05 was considered significant. The sample size: 125 for both groups. Data were represented as mean±SD of all. IFN-α, interferon-α; IL-2, interleukin-2.
Fig. 6 Progression-free survival of patients. Progression-free survival of patients was considered as time without any progression to new cutaneous/subcutaneous metastases (skin), lymph node metastases, or distant metastases (systemic). 0: At the time of completion of the intervention. The χ2-independence test was used for statistical analysis. A P<0.05 was considered significant. The sample size: 125 for both groups. Data were represented as mean±SD of all. IFN-α, interferon-α; IL-2, interleukin-2.CC BY-NC-ND · PubMed Central
Fig. 7 The total cost of treatment of patients. Repeated measures analysis of variance was used for statistical analysis. A P<0.05 was considered significant. Data were represented as mean±SD of all. The sample size: 125 for both groups. The cost was considered from the time of detection of malignant melanoma to the death. IFN-α, interferon-α; IL-2, interleukin-2.
Fig. 7 The total cost of treatment of patients. Repeated measures analysis of variance was used for statistical analysis. A P<0.05 was considered significant. Data were represented as mean±SD of all. The sample size: 125 for both groups. The cost was considered from the time of detection of malignant melanoma to the death. IFN-α, interferon-α; IL-2, interleukin-2.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Bi-xia T Lu S Zhi-hong C Chuan-liang C Xi-nan S Li-li M A phase II clinical trial of recombinant human interleukin-2 in treatment of advanced melanoma. Tumor 2011; 31: 1042– 1046.

Cited by

See all 11

Metadata

Authors
Li, S., Wu, X., Chen, P., Pei, Y., Zheng, K., Wang, W., Qiu, E., & Zhang, X.
Affiliations
  • Liaoning Cancer Hospital & Institute (CN)
  • China Medical University (CN)
Corresponding author
  • Li, Shenglong
  • Wu, Xixi
Venue
Anti-Cancer Drugs
Published
2019-04
Volume
30
Issue
4
Pages
402-409
ISSN
0959-4973 (ISSN-L)
OpenAlex
W2995216457
Cited by
11
References
28
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 1 · 2021: 1 · 2019: 1
FWCI
0.31
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Anti-Cancer Drugs (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
interferon-alpha, interleukin-2, melanoma, adjuvant immunotherapy, unresectable melanoma, progression-free survival, overall survival, brain metastases, adverse effects, treatment costs, Chinese patients
MeSH terms
Cutaneous Malignant Melanoma, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Interleukin-2, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Survival Rate, Interferon-alpha, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial. https://app.cochat.ai/papers/10.1097/cad.0000000000000741
The paper
Li, S., Wu, X., Chen, P., Pei, Y., Zheng, K., Wang, W., Qiu, E., & Zhang, X. (2019). Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000000741

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.